CINAINU® Receives FDA Breakthrough Status for Alopecia Areata Treatment

Legacy Healthcare's CINAINU® (LH-8), an investigational solution for moderate-to-severe alopecia areata, has received Breakthrough Therapy Designation from the FDA. This status aims to expedite the development and review process for the drug, which demonstrated significant hair regrowth in Phase 2/3 trials. The designation addresses an unmet need for patients, including children, seeking effective treatments for the condition.